DISCOUNT OPTIONSSCHEIN - MODERNA | Delayed Deutsche Boerse AG 07:41:34 2024-05-23 EDT | ||
| 1.81 EUR | +2.26% |
|
| Current month | -58.84% | ||
| 1 month | -60.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 1.81 | +2.26% |
| 24-05-22 | 1.77 | -40.20% |
| 24-05-21 | 2.96 | +0.68% |
| 24-05-20 | 2.94 | -16.00% |
| 24-05-17 | 3.5 | -2.23% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 07:41 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VU1FG2 |
| ISIN | DE000VU1FG21 |
| Date issued | 2023-01-03 |
| Strike | 175 $ |
| Maturity | 2024-06-21 (29 Days) |
| Parity | 10 : 1 |
| Emission price | 2.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.48 € |
|---|---|
| Lowest since issue | 1.64 € |
| Spread | 0.01 € |
| Spread % | 0.57% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
163.3
USD
Average target price
138.5
USD
Spread / Average Target
-15.19%
- Stock Market
- Certificates
- Certificat
